Bioxytran, Inc (BIXT) — SEC Filings
Bioxytran, Inc (BIXT) — 19 SEC filings. Latest: 8-K (Dec 15, 2025). Includes 8 8-K, 6 10-Q, 2 10-K.
View Bioxytran, Inc on SEC EDGAR
Overview
Bioxytran, Inc (BIXT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: On December 7, 2025, BIOXYTRAN, INC. filed an 8-K report detailing the departure of a director and the election of a new director. The filing also addresses compensatory arrangements for certain officers. The company, formerly known as U.S. Rare Earth Minerals, Inc., is incorporated in Nevada and op
Sentiment Summary
Across 19 filings, the sentiment breakdown is: 2 bearish, 17 neutral. The dominant filing sentiment for Bioxytran, Inc is neutral.
Filing Type Overview
Bioxytran, Inc (BIXT) has filed 8 8-K, 6 10-Q, 2 10-K, 2 S-1/A, 1 10-Q/A with the SEC between Mar 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (19)
Risk Profile
Risk Assessment: Of BIXT's 19 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not Reported |
| Net Income | -$1,600,922 |
| EPS | Not Reported |
| Debt-to-Equity | Not Reported |
| Cash Position | $14,499 |
| Operating Margin | Not Reported |
| Total Assets | Not Reported |
| Total Debt | $3,060,937 |
Key Executives
- David Platt
Industry Context
BIOXYTRAN, INC. operates in the highly competitive and capital-intensive pharmaceutical industry, specifically focusing on developing treatments for hypoxia and viral diseases. The company is in the early clinical stage, meaning it faces significant R&D hurdles and regulatory scrutiny. Success hinges on demonstrating therapeutic efficacy and safety, a process fraught with high failure rates and long development timelines.
Top Tags
10-Q (5) · pharmaceuticals (4) · corporate-action (3) · financials (3) · BIOXYTRAN (3) · Biotechnology (2) · 10-K (2) · sec-filing (2) · material-definitive-agreement (2) · financial-reporting (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $1.60M | Net loss for the nine months ended September 30, 2025, compared to $1.63M in 2024. |
| Accumulated Deficit | $20.52M | Increased from $18.92M at December 31, 2024, indicating ongoing losses. |
| Total Current Liabilities | $3.06M | Increased by 58.5% from $1.93M at December 31, 2024, signaling financial strain. |
| Derivative Liability | $419,206 | Increased by 124% from $186,652 at December 31, 2024, posing future risk. |
| Cash Balance | $14,499 | Increased from $5,154 at December 31, 2024, but remains critically low. |
| Short-term Loans from Affiliates | $300,327 | Primary source of cash flow from financing activities for the nine months ended September 30, 2025. |
| Total Operating Expenses | $1,235,224 | Decreased from $1,734,755 in the prior year, mainly due to G&A reductions. |
| Total Stockholders' Deficit | $2,904,643 | Worsened from $1,791,948 at December 31, 2024, reflecting continued losses. |
| Shares from Convertible Note | 15,121,870 | Potential dilution from the 2021 Note conversion at $0.071/share. |
| Shares from Preferred Stock Conversion | 217,148,195 | Significant potential dilution from Convertible Preferred Stock. |
| Revenue | $0 | No revenue reported for Q2 2025 or YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $1,000 | Consistent net loss for the quarter, showing ongoing operational expenses without income. |
| Net Loss (YTD 2025) | $2,000 | Consistent net loss for the six-month period, reflecting sustained pre-revenue operations. |
| Total Assets | $0 | No reported assets as of June 30, 2025, highlighting extreme financial fragility. |
| Period End Date | 20250331 | The end of the reporting quarter. |
Frequently Asked Questions
What are the latest SEC filings for Bioxytran, Inc (BIXT)?
Bioxytran, Inc has 19 recent SEC filings from Mar 2024 to Dec 2025, including 8 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BIXT filings?
Across 19 filings, the sentiment breakdown is: 2 bearish, 17 neutral. The dominant sentiment is neutral.
Where can I find Bioxytran, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bioxytran, Inc (BIXT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bioxytran, Inc?
Key financial highlights from Bioxytran, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BIXT?
The investment thesis for BIXT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bioxytran, Inc?
Key executives identified across Bioxytran, Inc's filings include David Platt.
What are the main risk factors for Bioxytran, Inc stock?
Of BIXT's 19 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Bioxytran, Inc?
Forward guidance and predictions for Bioxytran, Inc are extracted from SEC filings as they are enriched.